Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?

Martina C. Cornel, Heidi C. Howard, Daniel Lim, Vence L. Bonham, Kirmo Wartiovaara

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Clinical trials using somatic gene editing (e.g., CRISPR–Cas9) have started in Europe and the United States and may provide safe and effective treatment and cure, not only for cancers but also for some monogenic conditions. In a workshop at the 2018 European Human Genetics Conference, the challenges of bringing somatic gene editing therapies to the clinic were discussed. The regulatory process needs to be considered early in the clinical development pathway to produce the data necessary to support the approval by the European Medicines Agency. The roles and responsibilities for geneticists may include counselling to explain the treatment possibilities and safety interpretation.

Original languageEnglish
Pages (from-to)484-487
Number of pages4
JournalEuropean Journal of Human Genetics
Volume27
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019

Cite this

Cornel, Martina C. ; Howard, Heidi C. ; Lim, Daniel ; Bonham, Vence L. ; Wartiovaara, Kirmo. / Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?. In: European Journal of Human Genetics. 2019 ; Vol. 27, No. 3. pp. 484-487.
@article{36a75702a5cc444f973d7bebd1eb1a00,
title = "Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?",
abstract = "Clinical trials using somatic gene editing (e.g., CRISPR–Cas9) have started in Europe and the United States and may provide safe and effective treatment and cure, not only for cancers but also for some monogenic conditions. In a workshop at the 2018 European Human Genetics Conference, the challenges of bringing somatic gene editing therapies to the clinic were discussed. The regulatory process needs to be considered early in the clinical development pathway to produce the data necessary to support the approval by the European Medicines Agency. The roles and responsibilities for geneticists may include counselling to explain the treatment possibilities and safety interpretation.",
author = "Cornel, {Martina C.} and Howard, {Heidi C.} and Daniel Lim and Bonham, {Vence L.} and Kirmo Wartiovaara",
year = "2019",
month = "3",
day = "1",
doi = "10.1038/s41431-018-0309-x",
language = "English",
volume = "27",
pages = "484--487",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "3",

}

Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic? / Cornel, Martina C.; Howard, Heidi C.; Lim, Daniel; Bonham, Vence L.; Wartiovaara, Kirmo.

In: European Journal of Human Genetics, Vol. 27, No. 3, 01.03.2019, p. 484-487.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?

AU - Cornel, Martina C.

AU - Howard, Heidi C.

AU - Lim, Daniel

AU - Bonham, Vence L.

AU - Wartiovaara, Kirmo

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Clinical trials using somatic gene editing (e.g., CRISPR–Cas9) have started in Europe and the United States and may provide safe and effective treatment and cure, not only for cancers but also for some monogenic conditions. In a workshop at the 2018 European Human Genetics Conference, the challenges of bringing somatic gene editing therapies to the clinic were discussed. The regulatory process needs to be considered early in the clinical development pathway to produce the data necessary to support the approval by the European Medicines Agency. The roles and responsibilities for geneticists may include counselling to explain the treatment possibilities and safety interpretation.

AB - Clinical trials using somatic gene editing (e.g., CRISPR–Cas9) have started in Europe and the United States and may provide safe and effective treatment and cure, not only for cancers but also for some monogenic conditions. In a workshop at the 2018 European Human Genetics Conference, the challenges of bringing somatic gene editing therapies to the clinic were discussed. The regulatory process needs to be considered early in the clinical development pathway to produce the data necessary to support the approval by the European Medicines Agency. The roles and responsibilities for geneticists may include counselling to explain the treatment possibilities and safety interpretation.

UR - http://www.scopus.com/inward/record.url?scp=85058943163&partnerID=8YFLogxK

U2 - 10.1038/s41431-018-0309-x

DO - 10.1038/s41431-018-0309-x

M3 - Article

VL - 27

SP - 484

EP - 487

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 3

ER -